VT6 Stock Overview
A biotechnology company, focuses on the treatment of gene therapy and neurology diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Voyager Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.16 |
| 52 Week High | US$10.10 |
| 52 Week Low | US$5.01 |
| Beta | 0.91 |
| 11 Month Change | 14.19% |
| 3 Month Change | -13.61% |
| 1 Year Change | 0.081% |
| 33 Year Change | 90.20% |
| 5 Year Change | -53.72% |
| Change since IPO | -66.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| VT6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -0.4% | -1.8% |
| 1Y | 0.08% | -15.4% | 13.6% |
Return vs Industry: VT6 exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: VT6 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| VT6 volatility | |
|---|---|
| VT6 Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VT6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: VT6's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 162 | Al Sandrock | www.voyagertherapeutics.com |
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.
Voyager Therapeutics, Inc. Fundamentals Summary
| VT6 fundamental statistics | |
|---|---|
| Market cap | €349.82m |
| Earnings (TTM) | €8.27m |
| Revenue (TTM) | €131.75m |
42.3x
P/E Ratio2.7x
P/S RatioIs VT6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VT6 income statement (TTM) | |
|---|---|
| Revenue | US$143.77m |
| Cost of Revenue | US$113.16m |
| Gross Profit | US$30.61m |
| Other Expenses | US$21.58m |
| Earnings | US$9.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 21.29% |
| Net Profit Margin | 6.28% |
| Debt/Equity Ratio | 0% |
How did VT6 perform over the long term?
See historical performance and comparison